A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme

The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved chemotherapy drug temozolomide

Stanford is now accepting new patients for this trial. Please contact Jacob Wynne at 650-723-8843 for more information.

Investigator(s):

Intervention(s):

  • drug : Temozolomide
  • procedure : Stereotactic Radiosurgery

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must be made by surgical biopsy or excision - The tumor must be supratentorial in location - The planning target volume (tumor plus margin) must measure <= 150 cm^3 in volume - Age >=18 years - Life expectancy of at least 12 weeks - Patient must have adequate organ function to tolerate temozolomide (details in the protocol)

External Links

Explore related trials

Contact information

Primary Contact:

Jacob Wynne 650-723-8843

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: